Showing papers on "Female Sexual Arousal Disorder published in 2015"

Drugs in early clinical development for the treatment of female sexual dysfunction

Abstract: Introduction: There is growing recognition of female sexual dysfunction (FSD) as an important women’s health concern. Despite an increased awareness of the pathophysiologic components to FSD, currently, there are no drugs approved for the most common sexual complaint in women–decreased sexual desire. In response to an overwhelming demand for therapy for FSD, several drugs are undergoing development and testing.Areas covered: The aim of this paper is to provide the latest data on pharmacological treatments for FSD currently in Phase I and II clinical trials. These include topical alprostadil, bremelanotide (BMT), intranasal testosterone (TBS-2), intravaginal dehydroepiandrosterone (DHEA), sublingual testosterone with sildenafil, apomorphine (APO), bupropprion and trazodone. It should be noted that the definitions of FSD have recently been revised in the diagnostic and statistical manual for mental disorders (DSM) 5, with merging of hypoactive sexual desire disorder (HSDD) and female sexual arousal disorder...

Systems and methods for treating sexual disorders using electro-stimulation

Abstract: Systems and methods are provided for treating a sexual disorder such as erectile dysfunction (ED) or female sexual arousal disorder (FSAD). An electrical stimulation system may include an implantable stimulation unit, an external patient controller, and an external physician controller. The implantable stimulation unit has an array of electrodes disposed on one or more flexible substrates configured to conform to a patient's anatomy at the pelvic plexus. Post-implantation, the physician controller may direct the stimulation unit to stimulate with select electrode(s) of the array to determine which electrode configuration provides optimal sexual arousal. The patient controller may be used to cause the stimulation unit to stimulate using the optimal electrode configuration at desired times.

Female sexual function and heart rate variability.

Abstract: Few studies have examined the associations of resting heart rate variability (HRV) with female sexual function and behavior. Therefore, we welcome the recent study finding that women with below average resting HRV (as assessed by the standard deviation of NN intervals; SDNN) had lower sexual arousal and lower global sexual function than women with average or above average SDNN (while viewing a neutral film) (Stanton et al. 2015). The SDNN reflects relatively lower sympathetic activity and/or relatively higher parasympathetic activity. Those authors noted the lack of studies on female sexuality and HRV, but missed citing an important study which explored the associations of HRV with women’s frequency of orgasm produced by several different sexual behaviors (Costa and Brody 2012). In that study, it was found that women who had any orgasm triggered by penile-vaginal intercourse (PVI) without simultaneous clitoral masturbation (henceforth, vaginal orgasm) in the past month had higher resting HRV (as assessed by the standard deviation of heart rate, a relatively similar index of HRV) than women who did not have a vaginal orgasm in the past month (Costa and Brody 2012). Of note, orgasm produced by other sexual behaviors including PVI with concurrent clitoral masturbation for the orgasm, clitorally-focused partnered masturbation, oral sex, solitary masturbation, and anal sex were unrelated to resting HRV. Orgasm from vaginally-focused masturbation by the woman’s partner was nearly significantly associated with higher HRV, but this marginal association disappeared in multivariate analyses controlling for the other orgasm trigger frequencies, resulting in only vaginal orgasm being associated with women’s greater resting HRV. These findings were discussed in terms of lower HRV being a reflection of pathophysiological processes that can impair female orgasmic responsiveness specifically during PVI (Costa and Brody 2012). This raises the possibility that vaginal responsiveness is more easily adversely affected by psychological and physiological dysfunctional processes than responding to direct clitoral masturbation. The vagus nerve (the main driver of the parasympathetic nervous system influences on HRV) transmits afferent sensory information from the proximal vagina and cervix to the brain, but is not stimulated by the clitoris (Komisaruk and Whipple 1998; Komisaruk et al. 2004). Given that appropriate afferent vagal stimulation might increase (or ‘‘tune’’) efferent vagal activity on a relatively long-term basis (Gellhorn 1967), it is plausible that PVI may enhance HRV with concomitant health benefits (Costa and Brody 2012). These findings are congruent with another study finding that greater resting HRV (standard deviation of heart rate) was associated with greater PVI frequency in a sample of both sexes, and the sex of the research participant was not a significant confounding variable (Brody and Preut 2003). Unlike in the study by Stanton and colleagues, in these two studies, resting HRV was measured without an inserted vaginal probe (Brody and Preut 2003; Costa and Brody 2012), which Stanton and colleagues listed as a potential confounder in their own study. In a large nationally representative Czech sample, female sexual arousal disorder was related to lack of history of vaginal orgasm and difficulties in focusing on & Rui M. Costa rmscosta@gmail.com

Use of the combination of testosterone and tadalafil in the treatment of female sexual dysfunction

Abstract: The invention relates to the field of female sexual dysfunction. It specifically relates to the influence of the combination of testosterone or an analogue thereof and tadalafil on sexual health in female subjects with Female Sexual Dysfunction (such as Female Sexual Arousal Disorder (FSAD) or Female Sexual Desire Disorder (FSDD)). It further relates to the influence of the combination of testosterone or an analogue thereof and a compound capable of at least in part inhibiting smooth muscle constriction, for example a compound capable of at least in part inhibiting the adrenergic tone. The invention further discloses other combinatorial therapies in the treatment of Female Sexual Dysfunction.

Treating female sexual arousal disorder and related symptoms

Abstract: This invention relates to treating female sexual arousal disorder and/or improving female sexual response, and related symptoms, preferably with topical prostaglandin compositions.